Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon
Neuro-Oncology · 04.03.2024 · 26 (Supplement_1) · S3-S16
DOI: 10.1093/neuonc/noad258 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 04.03.2024. Verfasst von Chia-Lin Tseng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Glioblastoma, Radiation Oncology, Neurology. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Chemoradiotherapy is the standard treatment after maximal safe resection for glioblastoma (GBM). Despite advances in molecular profiling, surgical techniques, and neuro-imaging, there have been no major breakthroughs in radiotherapy (RT) volumes in decades. Although the majority of recurrences occur within the original gross tumor volume (GTV), treatment of a clinical target volume (CTV) ranging from 1.5 to 3.0 cm beyond the GTV remains the standard of care. Over the past 15 years, the incorporation of standard and functional MRI sequences into the treatment workflow has become a routine practice with increasing adoption of MR simulators, and new integrated MR-Linac technologies allowing for daily pre-, intra- and post-treatment MR imaging. There is now unprecedented ability to understand the tumor dynamics and biology of GBM during RT, and safe CTV margin reduction is being investigated with the goal of improving the therapeutic ratio. The purpose of this review is to discuss margin strategies and the potential for adaptive RT for GBM, with a focus on the challenges and opportunities associated with both online and offline adaptive workflows. Lastly, opportunities to biologically guide adaptive RT using non-invasive imaging biomarkers and the potential to define appropriate volumes for dose modification will be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
- Department of Radiation Oncology, Simcoe Muskoka Regional Cancer Program, Royal Victoria Regional Health Centre, University of Toronto, Toronto, Ontario, Canada.
- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA.
- Department of Radiation Oncology, Stanford University, Stanford, California, USA.
- Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Chia-Lin Tseng, Scott G Soltys, Jay Detsky, Arjun Sahgal
Förderung
- NCI NIH HHS
Zitieren
APA
Tseng, C. L., Zeng, K. L., Mellon, E. A., Soltys, S. G., Ruschin, M., Lau, A. Z., Lutsik, N. S., Chan, R. W., Detsky, J., Stewart, J., Maralani, P. J., & Sahgal, A. (2024). Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon. Neuro-Oncology, 26(Supplement_1), S3-S16. https://doi.org/10.1093/neuonc/noad258
Vancouver
Tseng CL, Zeng KL, Mellon EA, Soltys SG, Ruschin M, Lau AZ, et al. Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon. Neuro-Oncology. 2024;26(Supplement_1):S3-S16. doi:10.1093/neuonc/noad258
BibTeX
@article{Tseng2024,
author = {Tseng, Chia-Lin and Zeng, K Liang and Mellon, Eric A and Soltys, Scott G and Ruschin, Mark and Lau, Angus Z and Lutsik, Natalia S and Chan, Rachel W and Detsky, Jay and Stewart, James and Maralani, Pejman J and Sahgal, Arjun},
title = {Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {Supplement_1},
pages = {S3--S16},
doi = {10.1093/neuonc/noad258}
}
EUVIMED